Ranganath Kandala, MD
Geriatric Medicine · Sugar Land, TXNPI 1912101585
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,390, 6.1 times the $227 reported in 2020. Among geriatric medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$626
- Amgen$578
- Lilly USA, LLC$530
- AstraZeneca$325
- Bayer$298
- AbbVie$290
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,705100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $626 |
| Amgen(2 entities) | 33 | $578 |
| Lilly USA, LLC | 27 | $530 |
| AstraZeneca | 20 | $325 |
| Bayer | 16 | $298 |
| AbbVie | 13 | $290 |
| Boehringer Ingelheim | 13 | $270 |
| Optinose US, Inc. | 11 | $222 |
| Dexcom, Inc. | 7 | $180 |
| Otsuka America Pharmaceutical, Inc. | 8 | $174 |
| Exact Sciences | 6 | $126 |
| Abbott | 5 | $119 |
| Pfizer | 5 | $106 |
| Kowa Pharmaceuticals America, Inc. | 6 | $89 |
| Novartis | 5 | $86 |
| Esperion Therapeutics, Inc. | 5 | $83 |
| Sumitomo Pharma America, Inc. | 5 | $82 |
| Medtronic | 3 | $81 |
| Johnson & Johnson | 3 | $69 |
| GSK | 3 | $57 |
| Corcept Therapeutics | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
How this compares
$4,719 in reported general payments places this provider in the 95th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $184,464 |
| JardianceEmpagliflozin | 61 | $78,734 |
| JanuviaSitagliptin Phosphate | 60 | $73,218 |
| FarxigaDapagliflozin Propanediol | 48 | $70,432 |
| EliquisApixaban | 38 | $56,148 |
| XareltoRivaroxaban | 45 | $55,881 |
| LinzessLinaclotide | 34 | $39,720 |
| RybelsusSemaglutide | 15 | $36,795 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $32,950 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $28,185 |
| SynjardyEmpagliflozin/Metformin Hcl | 15 | $23,382 |
| MounjaroTirzepatide | 19 | $22,933 |
| EntrestoSacubitril/Valsartan | 12 | $18,154 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $17,817 |
| VascepaIcosapent Ethyl | 19 | $17,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $626 | $221,259115 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $270 | $135,065108 claims |
| AstraZenecaFarxiga | $325 | $70,43248 claims |
| PfizerEliquis | $106 | $56,14838 claims |
| Johnson & JohnsonXarelto | $69 | $55,88145 claims |
| AbbVieLinzess, Synthroid | $290 | $41,42678 claims |
| GSKTrelegy Ellipta, Shingrix | $57 | $31,75038 claims |
| Lilly USA, LLCMounjaro | $530 | $22,93319 claims |
| NovartisEntresto | $86 | $18,15412 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $15,35518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Sugar Land
- Arusha BavareSugar Land$2K
- Owen CapocyanSugar Land$1K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.